Börse:
36,900€
3,36%
Echtzeit-Aktienkurs Acceleron Pharma
Bid:
36,800€
Ask:
37,000€
| Allgemeine Informationen | ||
|---|---|---|
| Börsenwert: | 1,71 Mrd. EUR (46,26 Mio. x 36,900€) | |
| Website: | - | |
| Sektor: | Medizin / Biotechnologie | |
| News-Radar | |
|---|---|
| dpa-AFX Pro - | Newsbot - |
| dpa-AFX - | Reuters - |
| 2015 | 2016 | 2017 | 2018 | |
|---|---|---|---|---|
| KUV | 67,93 | 50,83 | 123,89 | 122,01 |
| KGV | - | - | - | - |
| Div. Rend. | - | - | - | - |
Echtzeit-Chart der Acceleron Pharma Aktie
Börsenkurse Acceleron Pharma
| Dollar Indikation | 40,529$ | 0 | 40,836$ | 0 | 40,682$ | 3,07% |
| Börse Stuttgart | 36,000€ | 2500 | 37,600€ | 2500 | 36,800€ | 5,14% |
| Lang & Schwarz | 36,800€ | 700 | 37,000€ | 700 | 36,900€ | 3,07% |
| Tradegate | 36,800€ | 140 | 37,000€ | 140 | 36,900€ | 3,36% |
| Euro Indikation | 36,800€ | 0 | 37,000€ | 0 | 36,900€ | 3,36% |
Fundamentaldaten der Acceleron Pharma Aktie
Aktuelle Geschäftsentwicklung
Sie benötigen die TraderFox Börsensoftware, um die aktuelle Geschäftsentwicklung einsehen zu können.
Income Statement: 10-Year-Summary
| Datum | Umsatz | EBIT | Gewinn | EPS | Dividende | KGV | KUV |
|---|---|---|---|---|---|---|---|
| 2018 | 13,99 Mio. | -118,90 Mio. | -118,87 Mio. | -2,59 | 0,00% | - | 122,01 |
| 2017 | 13,48 Mio. | -108,42 Mio. | -108,45 Mio. | -2,68 | 0,00% | - | 123,89 |
| 2016 | 27,77 Mio. | -56,99 Mio. | -57,01 Mio. | -1,52 | 0,00% | - | 50,83 |
| 2015 | 18,10 Mio. | -63,89 Mio. | -63,89 Mio. | -1,92 | 0,00% | - | 67,93 |
| 2014 | 14,63 Mio. | -51,26 Mio. | -51,26 Mio. | -1,63 | 0,00% | - | 81,79 |
| 2013 | 57,23 Mio. | -21,90 Mio. | -41,77 Mio. | -4,44 | 0,00% | - | 18,28 |
| 2012 | 15,25 Mio. | -32,58 Mio. | -59,64 Mio. | -6,21 | 0,00% | - | 23,53 |
| 2011 | 80,91 Mio. | 36,27 Mio. | 1,86 Mio. | 0,20 | 0,00% | 189,23 | 4,37 |
Profil der Acceleron Pharma Aktie
Acceleron Pharma, Inc. is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its product candidates include Luspatercept, designed to promote red blood cell production; dalantercept, for the treatment of patients with renal cell carcinoma; and ACE-083, designed for the treatment of focal muscle disorders. The company was founded by John L. Knopf and Thomas P. Maneates in June 2003 and is headquartered in Cambridge, MA.
TraderFox GmbH:
Impressum & Datenschutz -
Allgemeine Geschäftsbedingungen